Teva announced the launch of Tenofovir Disoproxil Fumarate Tablets, the first generic version of Gilead‘s Viread.
Viread, a nucleotide analog HIV-1 reverse transcriptase inhibitor, is indicated to treat HIV-1 infection in patients aged ≥2 years, in combination with other antiretroviral drugs. It is also indicated to treat chronic hepatitis B in patients aged ≥12 years.
Tenofovir Disoproxil undergoes hydrolysis and phosphorylations to convert to tenofovir diphosphate, which inhibits HIV-1 reverse transcriptase and HBV reverse transcriptase by competing with the natural substrate deoxyadenosine 5′-triphosphate and by DNA chain termination.
Tenofovir Disoproxil Fumarate Tablets are available as a 300mg strength in 30-count bottles.
For more information call (866) 832-8537 or visit TevaGenerics.com.